Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 28, Number 7—July 2022

Research Letter

Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Toshihiro Sato, Shinjiro Kodama, Keizo Kaneko, Junta Imai, and Hideki KatagiriComments to Author 
Author affiliation: Tohoku University Hospital, Sendai, Japan

Main Article

Figure

Clinical course after immune checkpoint inhibitors treatment initiation for type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination, Japan. Numbers above bars are percentage glycated hemoglobin values.

Figure. Clinical course after immune checkpoint inhibitors treatment initiation for type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination, Japan. Numbers above bars are percentage glycated hemoglobin values.

Main Article

Page created: April 19, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external